Levodopa/Carbidopa/Entacapone Teva (Carbidopa, Entacapone, Levodopa)

Levodopa is converted to dopamine in the brain, restoring deficient neurotransmission. Carbidopa blocks peripheral conversion of levodopa, allowing more to reach the central nervous system. Entacapone inhibits the COMT enzyme, slowing levodopa breakdown and extending its therapeutic action.

The exact dose is individualized and set by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing side effects.

Safety data are limited; the medication should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians typically evaluate alternatives and discuss risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Standard levodopa/carbidopa provides dopamine replacement but is metabolized quickly, leading to fluctuations. Adding entacapone (a COMT inhibitor) reduces peripheral breakdown, prolonging levodopa’s effect and often decreasing "off" periods, which can improve daily symptom stability compared with levodopa/carbidopa alone.

Store the tablets at temperatures below 25 °C in their original container, protecting them from moisture and direct light. Do not refrigerate or freeze. Keep out of reach of children and dispose of any expired product according to local regulations.

The medication is taken orally as a whole tablet, usually with a glass of water. It may be taken with or without food, but consistent timing relative to meals can help reduce gastrointestinal side effects. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include dyskinesia (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension, cardiac arrhythmias, and rare events such as neuroleptic malignant syndrome or anaphylaxis. Prompt medical attention is required if any of these symptoms develop.

Patients with known hypersensitivity to levodopa, carbidopa, entacapone, or any formulation components should avoid the drug. It is also contraindicated in individuals currently taking non‑selective MAO‑B inhibitors, and caution is advised for those with severe cardiovascular disease, uncontrolled psychiatric disorders, or significant hepatic impairment.